However, PD-L1 can also be used as a marker of immunotherapy efficacy, and the use of MDM2 inhibitors to increase PD-L1 expression in tumor cells or the TME in animal experiments with improved immunotherapy efficacy is a seemingly attractive therapy. The gene discussed is CD274; the disease is neoplasm.